✦ LIBER ✦

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

✍ Scribed by Kitrinos, Kathryn M.; Corsa, Amoreena; Liu, Yang; Flaherty, John; Snow-Lampart, Andrea; Marcellin, Patrick; Borroto-Esoda, Katyna; Miller, Michael D.

Book ID: 127270518
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 618 KB
Volume: 59
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.26686

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

No resistance to tenofovir disoproxil fu

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

✍ Andrea Snow-Lampart; Brandi Chappell; Maria Curtis; Yuao Zhu; Florence Myrick; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 582 KB

Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV). To date, no reports of HBV clinical resistance to TDF have been confirmed. In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepati

Randomized Comparison of Tenofovir Disop

Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

✍ Fung, Scott; Kwan, Peter; Fabri, Milotka; Horban, Andrzej; Pelemis, Mijomir; Han 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 639 KB

740 HBSAG KINETICS IN PATIENTS WITH CHRO

740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS

✍ P. Marcellin; E.J. Heathcote; M. Buti; Z. Krastev; I. Jacobson; R.A. de Man; G. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy of tenofovir disoproxil fumarat

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

✍ Gordon, Stuart C.; Krastev, Zahary; Horban, Andrzej; Petersen, Jörg; Sperl, Jan; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 817 KB

559 COST-EFFECTIVENESS SIMULATION ANALYS

559 COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TENOFOVIR) IN HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS-B (CHB) IN ITALY AND FRANCE

✍ B. Deniz; F. Everhard 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Cost Effectiveness Analysis Of Tenofovir

Cost Effectiveness Analysis Of Tenofovir Disoproxil Fumarate (Viread®) In The Treatment Of Patients With Chronic Hepatitis B (Chb) In Mexico

✍ Soto, H.; Botello, B.S.; Pizarro, M.; Rizzoli, A.; Gozález, L.A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB